BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23724362)

  • 1. Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia.
    Fernandez HH; Pagan F; Danisi F; Greeley D; Jankovic J; Verma A; Sethi K; Pappert EJ;
    Tremor Other Hyperkinet Mov (N Y); 2013; 3():. PubMed ID: 23724362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm.
    Fernandez HH; Jankovic J; Holds JB; Lin D; Burns J; Verma A; Sethi K; Pappert EJ
    Tremor Other Hyperkinet Mov (N Y); 2014; 4():238. PubMed ID: 25120942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects.
    Mitsikostas DD; Dekundy A; Hanschmann A; Althaus M; Scheschonka A; Pagan F; Jankovic J
    Curr Med Res Opin; 2021 Oct; 37(10):1761-1768. PubMed ID: 34384301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
    Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
    J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin type B for cervical dystonia.
    Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
    Truong DD; Gollomp SM; Jankovic J; LeWitt PA; Marx M; Hanschmann A; Fernandez HH;
    J Neural Transm (Vienna); 2013 Sep; 120(9):1345-53. PubMed ID: 23435927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia.
    Dressler D; Paus S; Seitzinger A; Gebhardt B; Kupsch A
    J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):1014-9. PubMed ID: 23687362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia.
    Fernandez HH; Pappert EJ; Comella CL; Evidente VG; Truong DD; Verma A; Jankovic J
    Tremor Other Hyperkinet Mov (N Y); 2013; 3():. PubMed ID: 23610743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
    Jost WH; Benecke R; Hauschke D; Jankovic J; Kaňovský P; Roggenkämper P; Simpson DM; Comella CL
    Drug Des Devel Ther; 2015; 9():1913-26. PubMed ID: 25897202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.
    Evidente VG; Fernandez HH; LeDoux MS; Brashear A; Grafe S; Hanschmann A; Comella CL
    J Neural Transm (Vienna); 2013 Dec; 120(12):1699-707. PubMed ID: 23779062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin type A therapy for cervical dystonia.
    Castelão M; Marques RE; Duarte GS; Rodrigues FB; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003633. PubMed ID: 29230798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.
    Jimenez-Shahed J
    Neuropsychiatr Dis Treat; 2012; 8():13-25. PubMed ID: 22275842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naïve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial.
    Mitsikostas DD; Dekundy A; Sternberg K; Althaus M; Pagan F
    Adv Ther; 2020 Oct; 37(10):4249-4265. PubMed ID: 32779096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II.
    Kent R; Robertson A; Quiñones Aguilar S; Tzoulis C; Maltman J
    Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
    Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
    J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study.
    Comella C; Hauser RA; Isaacson SH; Truong D; Oguh O; Hui J; Molho ES; Brodsky M; Furr-Stimming E; Comes G; Hast MA; Charles D
    Clin Park Relat Disord; 2022; 6():100142. PubMed ID: 35330880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study.
    Kongsaengdao S; Arayawithchanont A; Samintharapanya K; Rojanapitayakorn P; Maneeton B; Maneeton N
    Toxins (Basel); 2021 Oct; 13(10):. PubMed ID: 34678987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.